Skip to content

A Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation

A Prospective, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the XenMatrix™ Surgical Graft With Component Separation

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01305486
Acronym
XenMatrix
Enrollment
4
Registered
2011-02-28
Start date
2010-09-30
Completion date
2011-06-30
Last updated
2013-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hernia

Brief summary

This will be an observational study designed to collect early, short- and long-term clinical outcomes of the XenMatrix™ Surgical Graft for complex ventral hernia repair. Subjects will be expected to attend follow up visits at 1, 6, 12, 18 and 24 months following surgery.

Interventions

None listed

Sponsors

C. R. Bard
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be able to undergo study procedures. * Have signed an Informed Consent form (ICF). * Be diagnosed with a ventral or incisional hernia that cannot be closed primarily in the opinion of the investigator. * Requires a component separation repair with the use of a biological graft.

Exclusion criteria

* Subject is participating in another device or drug study. * Subject has a life expectancy less than 4 years at the time of enrollment. * Any condition in the opinion of the investigator that would preclude the use of the XenMatrix™ Surgical Graft, or preclude the subject from completing the follow-up requirements. * Any subject with a defect the surgeon feels he/she cannot fully close. * Subjects with a BMI \> 50. * Subjects with connective tissue disorders. * Subjects with a history of cirrhosis. * Subjects with renal failure requiring dialysis. * Subjects on or suspected to be placed on chemotherapy or systemic immunosuppressive medications during any part of the study. * Transplant recipients. * Subjects taking corticosteroids for \>6 months (pre or post surgery). * Any bowel leak or infection that would preclude the use of the XenMatrix™ Surgical Graft in the opinion of the investigator. * The subject lives approximately 2 hours away from the study site and compliance with follow up requirements will be difficult in the opinion of the investigator.

Design outcomes

Primary

MeasureTime frameDescription
To estimate the hernia recurrence rate of complex ventral hernias post repair with the XenMatrix™ Surgical Graft utilizing the component separation technique with several different tissue plane placements of the graft for up to 24 months post surgery.2 YearsAny hernia which is identified or confirmed by the investigator in approximately the same position as the hernia repair during any follow up visit after a XenMatrix™ surgical graft has been placed will be considered a recurrent hernia.

Secondary

MeasureTime frameDescription
To assess perioperative, short-term and long-term complications in subjects with complex hernias repaired with XenMatrix™ Surgical Graft and component separation.2 YearsProcedural and device related AEs collected from surgery until 24 months post surgery.
To assess the procedural time for XenMatrix™ Surgical Graft placement with component separation.Day 0Procedure time will be defined as beginning when the investigator makes the initial skin incision and ending when the skin closure is completed (skin to skin).
To assess changes in subject quality of life (QOL) post repair with a XenMatrix™ Surgical Graft with component separation.2 yearsChanges in QOL will be assessed from baseline to 24 months utilizing the Short Form-36 (SF-36) version 2.
To assess clinical outcomes based on the tissue plane placement of the XenMatrix™ Surgical Graft.2 yearsSubjects who have their grafts placed in different tissue planes will have their recurrence rate, complication type and frequency examined to determine if there are any gross differences.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026